Core Insights - Cryoport Inc reported strong third-quarter financial results, with revenue of $44.2 million, surpassing analyst expectations of $41.36 million, and a loss of 18 cents per share, better than the anticipated loss of 21 cents per share [2][3] Financial Performance - Total revenue increased by 15% year-over-year, driven by a 36% rise in Commercial Cell and Gene Therapy revenue [2] - The company achieved a gross margin of 48% in Q3 and showed improvements in adjusted EBITDA [4] Operational Highlights - Cryoport supported 745 global clinical trials as of September 30, with 83 trials currently in Phase 3 [3] - The company ended the quarter with $421.3 million in cash, cash equivalents, and short-term investments [3] Shareholder Actions - Cryoport repurchased 483,397 shares of its common stock at an average price of $7.73 per share, with approximately $65.9 million remaining under its share repurchase program [4] Future Outlook - The company raised its fiscal 2025 revenue guidance to a range of $170 million to $174 million [5] - Cryoport maintains its position as the only pure-play end-to-end temperature-controlled supply chain platform supporting a large portfolio of clinical and commercial Cell & Gene therapies [5]